Urgent Diagnosis and Management of Guillain‑Barré Syndrome

Diagnostic Indicators

Early sensory paresthesias in the extremities, face, and saddle region strongly suggest Guillain‑Barré syndrome and warrant immediate hospital admission for immunotherapy [1][2].
Electrophysiologic studies performed within the first week may be normal or show only subtle abnormalities such as isolated F‑wave changes; these findings do not exclude Guillain‑Barré syndrome [3][4]5.
Multiregional involvement (hands, feet, face, and perineal area) is characteristic of a diffuse polyradiculoneuropathy consistent with Guillain‑Barré syndrome [1][2].
Sensory symptoms often precede motor weakness in Guillain‑Barré syndrome [2][6].
Bilateral facial paralysis is a common manifestation of Guillain‑Barré syndrome [6][3].
Saddle‑area sensory loss raises concern for autonomic dysfunction affecting bladder and intestinal function [2][6].

Perform lumbar puncture to assess for albuminocytologic dissociation; however, 30–50 % of patients have a normal CSF protein level during the first week [6][3]4.
A pleocytosis > 50 cells/µL on CSF analysis suggests an alternative diagnosis such as leptomeningeal malignancy or infectious polyradiculitis [6][4]5.
If the initial electromyography is normal or minimally abnormal, repeat the study in 2–3 weeks to capture evolving changes [3][4]5.
Assess forced vital capacity and respiratory muscle strength because approximately 20 % of patients develop respiratory failure 1.

Development of bulbar or respiratory muscle weakness mandates intensive‑care monitoring 6.
Autonomic instability (e.g., labile blood pressure, cardiac arrhythmias) is an ICU admission criterion 1.
A vital capacity < 20 mL/kg or < 1 L indicates high risk of respiratory compromise and requires ICU care [1][2].

Initiate immunotherapy without awaiting anti‑ganglioside antibody results 5.
Intravenous immunoglobulin (0.4 g/kg/day for 5 days) and plasma exchange (200–250 mL/kg over 5 sessions) have equivalent efficacy and should be started promptly 2.

Measure forced vital capacity every 4–6 hours to detect early respiratory decline 6.
Continuous cardiac and blood‑pressure monitoring is essential for detecting autonomic dysfunction 1.
Vigilantly monitor for bulbar dysfunction to prevent aspiration [1][2].

The progressive phase usually lasts < 2 weeks, with maximal disability reached during this period [1][2].
60–80 % of patients regain independent ambulation by 6 months 1.
Mortality ranges from 3–10 % even with optimal care 1.
Functional recovery may continue for more than 3 years after onset 2.
Recurrence is uncommon, occurring in 2–5 % of cases [1][2].
Early initiation of immunotherapy improves outcomes; treatment should not be delayed for complete electrophysiologic confirmation or CSF albuminocytologic dissociation [1][2].

Normal CSF protein in the first week does not rule out the disease, but persistent normal values should prompt reconsideration [6][3]4.
Absence of overt motor weakness at presentation does not exclude Guillain‑Barré syndrome; sensory symptoms may precede weakness [2][6].
Persistent early bladder/intestinal dysfunction, marked asymmetry, a clear sensory level, hyperreflexia or clonus, and disease progression > 4 weeks are features that raise doubt for Guillain‑Barré syndrome and suggest alternative diagnoses [6][3]4.